Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

Kwo PY, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370-380.

Publication Type:

Journal Article

Authors:

P Y Kwo; Gitlin, N.; Nahass, R.; et, al

Source:

Hepatology, Volume 64, Issue 2, p.370-380 (2016)

Cited On:

Export Citation:
RIS Format
Top